Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Rhinosinusitis With Nasal Polyposis Clear all
Completed Not applicable Interventional Results available

Comparison of Nasal Steroids After FESS in CRSwNP

NCT02194062
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
fluticasone nasal spray, Budesonide head upright, Budesonide head forward
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
New Haven, Connecticut • Stratford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 5, 2026, 5:37 AM EDT
Terminated Phase 2 Interventional Results available

Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT02569437
View directory record Official record
Conditions
Polyp of Nasal Sinus
Interventions
Doxycycline, methylprednisolone, nasal saline spray, Flonase, sugar pill
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

GB001 in Adult Participants With Chronic Rhinosinusitis

NCT03956862
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
GB001, Placebo
Drug
Lead sponsor
GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
29
States / cities
Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 5, 2026, 5:37 AM EDT
Recruiting Phase 4 Interventional

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

NCT05094570
View directory record Official record
Conditions
Nasal Polyps, Staphylococcus Aureus
Interventions
Dupilumab Prefilled Syringe
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT04362501
View directory record Official record
Conditions
Chronic Sinusitis
Interventions
dupilumab, placebo
Biological · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery

NCT02562924
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
MEDIHONEY®, Budesonide, Normal saline sinus rinse, Prednisone, Endoscopic sinus surgery, nasal saline spray
Device · Drug · Procedure
Lead sponsor
University of Vermont Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 5, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional Results available

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

NCT03102190
View directory record Official record
Conditions
Sinusitis, Nasal Polyps
Interventions
Verapamil Hydrochloride Intranasal
Drug
Lead sponsor
Benjamin Bleier
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 5, 2026, 5:37 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

NCT04157335
View directory record Official record
Conditions
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Interventions
Benralizumab 30 mg, Matched placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
Huntington Beach, California • Grand Junction, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps

NCT02170337
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
AMG 282, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Santa Monica, California • Aurora, Colorado • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 5, 2026, 5:37 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps

NCT02285283
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Itraconazole, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)

NCT03358329
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
S8 Sinus Implant
Combination Product
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Sacramento, California • New Haven, Connecticut • Naperville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

NCT04851964
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Experimental: Tezepelumab, Placebo, Mometasone furoate or equivalent intranasal corticosteroid
Biological · Other · Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Newport Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

NCT06914908
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Lunsekimig, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
9
States / cities
La Jolla, California • Roseville, California • Boise, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

NCT06454240
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
lunsekimig, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
14
States / cities
La Jolla, California • Roseville, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training

NCT07681973
View directory record Official record
Conditions
Smell Loss, Chronic Rhinosinusitis (CRS)
Interventions
Smell Training
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Nasal Polyps

NCT02291549
View directory record Official record
Conditions
Chronic Sinusitis, Nasal Polyposis
Interventions
S8 Sinus Implant, Mometasone furoate nasal spray, Sham
Drug · Procedure
Lead sponsor
Intersect ENT
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Birmingham, Alabama • Irvine, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 5, 2026, 5:37 AM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

Mechanisms of Smell Improvement With Dupilumab.

NCT05964465
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
Dupilumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Charleston, South Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps

NCT06691113
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Murrieta, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Recruiting No phase listed Observational

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.

NCT06892704
View directory record Official record
Conditions
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Smell Loss
Interventions
Dupilumab - Standard Dose
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 5, 2026, 5:37 AM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Adjunctive Treatment for Chronic Rhinosinusitis With Nasal Polyposis

NCT03607175
View directory record Official record
Conditions
Chronic Rhinosinusitis, Nasal Polyps
Interventions
Triamcinolone-impregnated CMC foam, Propel Stent
Drug · Device
Lead sponsor
Marina Boruk
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 5, 2026, 5:37 AM EDT
Completed Phase 4 Interventional Results available

EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients

NCT04998604
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 5, 2026, 5:37 AM EDT
Recruiting No phase listed Observational

CRS Questionnaire Validation Project

NCT06970977
View directory record Official record
Conditions
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Interventions
Not listed
Lead sponsor
The European Forum for Research and Education in Allergy and Airway Diseases
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Santa Monica, California • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 5, 2026, 5:37 AM EDT